4:31 pm Biomarin Pharm confirms FDA approval for VIMIZIM (elosulfase alfa) for the treatment of patients with Morquio A syndrome – HedgeChatter

4:31 pm Biomarin Pharm confirms FDA approval for VIMIZIM (elosulfase alfa) for the treatment of patients with Morquio A syndrome

15 Feb

4:31 pm Biomarin Pharm confirms FDA approval for VIMIZIM (elosulfase alfa) for the treatment of patients with Morquio A syndrome

Bystocknews BMRN, stock Comments Off

View todays social media effects on BMRN

View the latest stocks trending across Twitter. Click to view dashboard

See who BioMarin is hiring next, click here to view

Author